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Letters to the Editor758which, differing from ATTR, there is no genetic diagnostic
standard) (Fig. 3).
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Figure 3. Role of 99mTc-DPD Scintigraphy in the Diagnostic Workup
Proposed clinical application of 99mTc-DPD in elderly patients with an echocard
a nondilated left ventricle (LV). Once a plasma-cell dyscrasia has been excluded
cardiac amyloidosis (strong myocardial visual uptake of 99mTc-DPD) and patient
of 99mTc-DPD). The differential diagnosis between SSA and ATTR requires deoxy
abbreviations as in Figures 1 and 2.amyloidosis. Int J Cardiol 2011 Jul 15 [E-pub ahead of print].Myocardial Imaging
for Mitochondrial
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The editorial by Strauss and Schoder (1) indicates that all useful
myocardial perfusion tracers, regardless of chemical structure,
mechanism of uptake, and retention, follow the Sapirstein princi-
ple, even when, save perhaps for 15O-water, they actually fail to
conform to the essential requirement postulated by Sapirstein (2)
for such a tracer; namely, first-pass extraction fraction of 1. The
editorial goes on to state that such tracers “. . . still provide accurate
measurements of regional and absolute [emphasis added] perfusion
and perfusion reserve if imaging is performed before significant loss
of indicator from the tissue” (1). We performed an additional
analysis of the data pertinent to the relationship between 4-[18F]-
Tetraphenylphosphonium (18F-TPP) measurement of absolute myo-
cardial blood flow (MBF) and corresponding microsphere measure-
ments of absolute MBF under conditions of adenosine stimulation
with phenylephrine support (Fig. 1) to further address the issue
raised by Strauss and Schoder (1) in their editorial.
In brief, we used all the ex vivo tissue samples (n 112) from all
the animals (n  6) reported in our study (3). Each myocardial
sample had a microsphere measurement of absolute MBF and a
well counter determined measure of 18F-TPP concentration. We
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Letters to the Editor 759absolute MBF by 18F-TPP and plotted the value (MBFapparent)
versus microsphere MBF in the same tissue sample (see Fig. 1A,
hown in more detail in Fig. 1B; data for MBF 2 ml/min/g). It
s evident there is no correlation between absolute values of MBF
etermined by 18F-TPP and radiolabeled microspheres, notwith-
tanding the left ventricular blood and myocardial time activity
urves shown in Figure 4 of Gurm et al. (3).
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Figure 1. MBFado (18F-TPP) Apparent Versus Microspheres
(A) Absolute MBFapparent (ml/min/g) as measured by 18F-TPP is plotted as
It is evident at absolute MBF 2 ml that absolute values of MBFapparent by
of true MBF up to 17 ml/min/g and so grossly and uniformly underestimate
MBFapparent as measured by 18F-TPP is plotted as a function of microspher
MBF 2 ml that absolute values of MBFapparent by 18F-TPP show considera
few on or close to it. Note also 18 data points with value of 1 ml/min/g for M
The line of identity is shown for reference. (C) The 18F-TPP extraction fractio
method of Di Rocco et al. (4) is shown here as a function of microsphere MB
[4] deﬁned ExtFx as MBFapparent/MBFmicrospheres. Since by deﬁnition ExtF
MBFapparent  MBFmicrospheres] were excluded from this analysis.) Note s
[GraphPad Software, Inc., La Jolla, California], robust method) used to ﬁt the
The solid black line includes all data points ﬁt to a biexponential function, w
(green dashed line) is excellent (R2  0.84) and demonstrates rapid decline
decline thereafter as MBF increases to as much as 17 ml/min/g (ExtFx 0.002).Further, once true MBF exceeds 1.5 to 2.0 ml/min/g, values of
absolute MBF by 18F-TPP demonstrate an essentially flat line very
far below the line of identity for true MBF (i.e., grossly and
uniformly underestimate true MBF). Unsurprisingly, the line looks
very much like that for sestamibi shown in Figure 1 of Di Rocco et
l. (4), only lower in terms of absolute, and essentially constant,
alue along the ordinate. Thus, like sestamibi, 18F-TPP appears to
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Letters to the Editor760be useful for determination of relative (Fig. 3A, Fig. 6 of Gurm et
al. [3]) but not absolute MBF (Figure 3B of Gurm et al. [3]).
Finally, Figure 1C shows that extraction fraction (ExtFx) for
18F-TPP, computed per Di Rocco et al. (4), exhibits relatively
rapid decline between MBF 0 to 2 ml/min/g (0.4 to 0.2) with
slow progressive decline thereafter as MBF increases to as much as
17 ml/min/g (ExtFx 0.002). Accordingly, low and ever-declining
(albeit slowly) ExtFx as MBF increases from 2 to 17 ml/min/g
offers a very plausible explanation for the data shown in Figure 1A
here and Figure 3B of Gurm et al. (3).
The reasons for low myocardial 18F-TPP extraction fraction,
similar, although less than that of sestamibi, likely are multifactorial
and, we agree, require additional study. However, flow dependence,
common to all less-than-perfect Sapirstein flow tracers and physico-
chemical properties of the molecule, including its positive charge, likely
play important roles. It should be recalled that the positive charge
would be expected to cause 18F-TPP (and sestamibi) to be repelled by
the myocyte cell membrane (lipophilic nature notwithstanding) during
systole when the membrane is depolarized and the net charge across it
is positive, an effect that will increase with increasing heart rate (more
time in systole) and also with coronary stenosis severity, as phasic flow
reversal occurs with increasing fraction of all flow occurring in systole
as stenosis severity increases (5). Finally, both the cytoplasmic and
mitochondrial membrane potentials, which may be dissociated
from MBF by a variety of interventions, are very likely to play a role
and, we agree, certainly merit further investigation.
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REPLY
We applaud the additional measurements made by Dr. Gewirtz et al.
to support their hypothesis that 4-[18F]-tetraphenylphosphonium
(18F-TPP) can be used to measure relative, but not absolute, myocar-
ial perfusion. The investigators analyzed a total of 112 samples to
erify the relationship of microsphere determined–perfusion to18F-TPP activity (1). The additional data support the results reportedin the paper, namely that 18F-TPP cannot be used as an indicator of
bsolute myocardial blood flow.
Because these results were unexpected, we asked a consultant, Dr.
einrich R. Schelbert, to independently review the data. Dr. Schelbert
sks whether this conclusion is universally valid. In their reply, the
uthors present a data plot indicating first-pass extraction fractions (E)
f 20% to 40% for flows (F) ranging from 0.4 to 2.0 ml/min/g. Yet, the
xperimental approach, as adopted in the current investigation fromDi
occo et al. (2), might underestimate E. In the Di Rocco study (2), the
onlinear regression equations between F and the radiotracer net
ptake in canine myocardium predict a flow of 0.76 ml/min/g, an E
alue of only 0.32. This value is substantially lower than the E of 0.66
eported in another study (3) and more consistent with observations in
uman myocardium. Second, the inverse relationship between E and
, as shown in Figure 1C in the letter by Gewirtz et al., offers a means
or quantifying F, provided that the relationship between E and F is
onstant between subjects. There is, however, considerable scatter of
he data around the regression line. Inspection of the data suggests
everal “families” of data points. If each of these data families were
btained from different animals, it might indicate considerable inter-
nimal variations in E (or the net retention of tracer in myocardium).
f the tracer retention depends on the mitochondrial membrane
otential, where a potential-dependent forward transport of radiotracer
rom cytosol into mitochondria competes with flow-dependent back
iffusion of radiotracer, is it possible that the observed variability
esulted from interanimal differences in mitochondrial membrane
otentials that ranged from about 65 to 112 mV, and thus varied
onsiderably between animals, as shown in Figure 1 of Gurm et al. (1)?
mportantly, did the experimental study conditions—including anes-
hetics, positive inotropic drugs, and vasodilator agents—account for
his variability? If this variability does not exist under normal condi-
ions in animals and in humans, and E for 18F-TTP would be more
stable, it might thus enable quantitative measurements of myocardial
blood flow.
Despite the very low extraction, the myocardial images in Figure
6 of Gurm et al. (1) have a very good myocardial-to-background
ratio, and excellent contrast between regions of ischemia and
normal myocardium. The image quality is particularly surprising
because the positron emission tomography imaging device was
manufactured more than 20 years ago.
As a result, we must conclude that the additional analysis supports
the comments of Dr. Gewirtz et al. that in these experiments 18F-TPP
distribution does not reflect absolute myocardial perfusion. However,
viewing the flow data as “families” of curves, and considering the
quality of the myocardial images as well as analysis of the normalized
data, the tracer may be very useful in the clinic.
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